Bilateral Retinal Angiomatous Proliferation in a Variant of Retinitis Pigmentosa

Case Reports in Ophthalmological Medicine. 2019;2019 DOI 10.1155/2019/8547962

 

Journal Homepage

Journal Title: Case Reports in Ophthalmological Medicine

ISSN: 2090-6722 (Print); 2090-6730 (Online)

Publisher: Hindawi Limited

LCC Subject Category: Medicine: Ophthalmology

Country of publisher: United Kingdom

Language of fulltext: English

Full-text formats available: PDF, HTML, ePUB, XML

 

AUTHORS


G. Aloe (Unit Retinal Pathology PTV Foundation, Tor Vergata University, Rome, Italy)

C. M. De Sanctis (Unit Retinal Pathology PTV Foundation, Tor Vergata University, Rome, Italy)

C. Strafella (Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy)

R. Cascella (Molecular Genetics Laboratory UILDM, Santa Lucia Foundation, Rome, Italy)

F. Missiroli (Unit Retinal Pathology PTV Foundation, Tor Vergata University, Rome, Italy)

M. Cesareo (Unit Retinal Pathology PTV Foundation, Tor Vergata University, Rome, Italy)

E. Giardina (Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy)

F. Ricci (Unit Retinal Pathology PTV Foundation, Tor Vergata University, Rome, Italy)

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 14 weeks

 

Abstract | Full Text

Purpose. To describe the first case of bilateral retinal angiomatous proliferation (RAP) in a patient with a variant of retinitis pigmentosa (RP). Case Report. An 85-year-old man with RP presented with visual acuity decrease and metamorphopsia in the left eye (LE). Fundus examination revealed typical signs of RP in both eyes, associated with intraretinal macular hemorrhage in the LE. Multimodal imaging, using Colour fundus Photography, Fluorescein (FA), and Indocyanine Green Angiography (ICGA) as well as Spectral-Domain Optical Coherence Tomography (SD-OCT) and Optical Coherence Tomography Angiography (OCTA), revealed a type 3 neovascular lesion in the involved eye. Genetic testing (NGS analysis) was performed to search for genetic variants correlated with the disease phenotype displayed by the patient. The patient was treated with intravitreal injections of bevacizumab, according to a fixed protocol of bimonthly injections plus a booster dose at second month. After 9 months, he was referred for visual acuity decrease and metamorphopsia in the fellow eye, where SD-OCT/OCTA showed a type 3 neovascular lesion in the right eye (RE). He was scheduled for intravitreal injections of bevacizumab. In both eyes, treatment with intravitreal bevacizumab was successful.